AveXis Inc

AveXis — Technical Presentation (May 2016)

21 slides from AveXis's technical presentation, May 6, 2016

  1. Slide 1: Disclosures: Jerry R Mendell, MD

    Disclosures: Jerry R Mendell, MD I have never had any investment in any product that I have tested in Clinical Trial I serve as a consultant to AveXis, Inc. who is sponsoring this SMA gene therapy trial I also serve as a consultant to Sarepta Therapeutics in the eteplirsen trial for DMD

  2. Slide 2: Spinal Muscular Atrophy (SMA) Type 1

    Spinal Muscular Atrophy (SMA) Type 1 Werdnig-Hoffman Onset < 6 mos, never sit!; death <2years Hypotonia, weakness; legs > arms; typical frog leg position Bulbar muscle weakness: weak suck and swallow Require substantial nutritional support Nutritional failure is a major complication - 50% on feeding

  3. Slide 3: Major Milestones in SMA History

    Major Milestones in SMA History Leading Genetic Cause of Infant Mortality ~1 in 10,000 live births 1995: Homozygous Deletion SMN1 Chr 5q13 Two Forms SMN in humans: SMN1(T), SMN2(C) NORMAL INDIVIDUAL SMN genes SMN protein SMN1 SMN2 SMN2 SMA INDIVIDUAL Multiple Copies of SMN2 modify Phenotype Function

  4. Slide 4: Pre Clinical Predicts Clinical Outcomes

    *Pre Clinical Predicts Clinical Outcomes Efficacy of scAAV9.CB.hSMN is dose and time dependent in D7 SMA Mouse P1 Dose 3.3 e 14 vg/kg prolongs survival >400 days A five-fold reduction in dose (6.7X 1013 vg/kg) reduces mean survival to 35 days Treatment at P5 results in survival to 28 days Treatment

  5. Slide 5: Phase 1 Trial Design

    Phase 1 Trial Design 6 *Patients may be put on noninvasive ventilator support (BiPAP) for <16 hours/day at discretion of their physician or study staff TRIAL OVERVIEW Route of Administration IV infusion via peripheral limb vein Prednisolone 1 mg/kg 1day Pre-GT Trial Design Open-label, dose-escalatio

  6. Slide 6: Sample Size and Dosing Cohorts Phase 1 SMA Gene Therapy Trial

    Sample Size and Dosing Cohorts Phase1 SMA Gene Therapy Trial 15 SMA patients have been enrolled - Ages 0.9 to 7.9 months 9 patients in original IND with amendment for an additional 6 IV infusion (AAV9) in peripheral vein - Cohort 1 6.7 X 1013 vg/kg n=3 - Cohort 2: 2.0 X 1014 vg/kg n=12 Prednisolone

  7. Slide 7: Intravenous Delivery x 1 Hour

    Intravenous Delivery x1 Hour

  8. Slide 8: Natural History of SMA Type 1

    Natural History of SMA Type 1 9 *Survival = no death, or no need for 16-hr/day ventilation continuously for 2 weeks, in the absence of an acute reversible illness Finkel RS, et al. Neurology 2014;83:810–7 Pediatric NM Clinical Research Network for SMA 90% of SMA Type 1 patients will not survive to t

  9. Slide 9: Survival Data – Ongoing Phase 1 Trial – 01Apr2016

    Survival Data – Ongoing Phase 1 Trial – 01Apr2016 Cohort 1 6.7E13 vg/kg Cohort 2 2.0E14 vg/kg PNCR (Finkel) 2014 Natural History Study: Day of Gene Transfer SURVIVAL DATA * A month is defined as 30 days 75% event-free 50% event-free 25% event-free 8% event-free 4/4 reached 8% no death 9/9 reached 25

  10. Slide 10: CHOP INTEND vs. Age: Cohort 1 – 01Apr2016

    CHOP INTEND vs. Age: Cohort 1 – 01Apr2016 Dashed line denotes missing data for reasons noted below: E.01 – follow-up on Month 17 cancelled due to SAE hospitalization; full CHOP INTEND not conducted on Months 19, 20, and 21 due to broken right arm; full CHOP INTEND not conducted on Months 26 and 27 d

  11. Slide 11: CHOP INTEND vs. Age: Cohort 2 – 01Apr2016

    CHOP INTEND vs. Age: Cohort 2 – 01Apr2016 Dashed line denotes missing data for reasons noted below: E.04 – full CHOP INTEND not conducted on Months 14 and 15 due to body cast for scoliosis; CHOP INTEND not conducted on Month 19 due to scoliosis surgery recovery; CHOP INTEND not conducted on Month 20

  12. Slide 12: CHOP INTEND vs. Age – 01Apr2016

    CHOP INTEND vs. Age – 01Apr2016 COHORT 1 (n=3) Baseline Age (months): 5.9 [median], 6.3 [mean] Current Age (months): 25.7 [median], 26.7 [mean] Mean CHOP INTEND Increase: 8.7 points COHORT 2 (n=12) Baseline Age (months): 3.1 [median],3.4 [mean] Current Age (months):11.7 [median],12.3 [mean] Mean CHO

  13. Slide 13: Change in CHOP INTEND Scores – 01Apr2016

    Change in CHOP INTEND Scores – 01Apr2016 COHORT 1 (n=3) Baseline Age (months): 5.9 [median], 6.3 [mean] Current Age (months): 25.7 [median], 26.7 [mean] Mean CHOP INTEND Increase: 8.7 points COHORT 2 (n=12) Baseline Age (months): 3.1 [median], 3.4 [mean] Current Age (months): 11.7 [median], 12.3 [me

  14. Slide 14: Nutritional Support – 01Apr2016

    Nutritional Support – 01Apr2016 Bulbar weakness in SMA Type I leads to impaired swallowing, malnutrition, and growth failure Median age of growth failure is 7 months of age2 Standard of Care currently recommends nutritional support as soon as feeding difficulties are present (NG/NJ tube or Gastrosto

  15. Slide 15: Pulmonary Support Data – 01Apr2016

    Pulmonary Support Data – 01Apr2016 Respiratory Support Status of AVXS-101 Patients No patient requires permanent ventilation Cohort 1 patients (n=3) are over 24.0 months of age, when <8% are predicted to be surviving or free of permanent ventilation1 Cohort 2 patients (n=6) are over 13.6 months of a

  16. Slide 16: Safety Data – Ongoing Phase 1 Trial – 01Apr2016

    Safety Data – Ongoing Phase 1 Trial – 01Apr2016 SAFETY AND TOLERABILITY OBSERVATIONS 74 confirmed AEs and 22 were deemed SAEs Only two of the SAEs were treatment-related on the basis of laboratory tests showing elevated liver function enzymes (LFEs), experienced by two patients without clinical mani

  17. Slide 17: Summary: Ongoing Phase 1 Data – 01Apr2016

    Summary: Ongoing Phase 1 Data – 01Apr2016 AVXS-101 appears to have a favorable safety profile and appears to be generally well tolerated A total 74 adverse events, 22 SAEs and 52 non-serious AEs 2 SAEs were treatment related and included elevated LFE 3 mild/moderate AEs were treatment related and in

  18. Slide 18: Dosed at months/weeks post GT

    Dosed at 4 months 6 weeks post GT Dosed at 27 days 4 months post GT 19

  19. Slide 19: Dosed at months post GT

    20 Dosed at 2 months 6 mo post GT

  20. Slide 20: Making Great Progress !!

    Making Great Progress !! Thanks to the Team at NCH Brian Kaspar Tom Prior Samiah Al-Zaidy Carlos Miranda Richard Shell Chris Petek Dave Arnold Katie Church Louise Rodino-Klapac Sarah Corcoran Linda Lowes Kathrin Meyer Lindsay Alfano John Kissel Kate Berry Kevin Foust Arthur Burghes Lindsey Braun Tea

  21. Slide 21: Making Great Progress !!

    Making Great Progress !! * Thanks to the Team at NCH Brian Kaspar Tom Prior Samiah Al-Zaidy Carlos Miranda Richard Shell Chris Petek Dave Arnold Katie Church Louise Rodino-Klapac Sarah Corcoran Linda Lowes Kathrin Meyer Lindsay Alfano John Kissel Kate Berry Kevin Foust Arthur Burghes Lindsey Braun *

AveXis — Technical Presentation (May 2016) on 6ix